
News|Videos|June 8, 2018
Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC
Author(s)Apar Kishor Ganti, MD, MS
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Advertisement
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
2
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
3
How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?
4
EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma
5
















































































